Sign In
Buy HIMS
$27.77
+0.730 (+2.70%)
At Close: Jul 31, 2026
Hims & Hers Gains 5% on Insider Buying
01:19pm, Wednesday, 27'th May 2026
Hims and Hers Health, Inc. (HIMS) rose 5.07% intraday after director David B. Wells purchased $1.17 million in Class A common stock, acquiring 48,400 shares. Well
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
12:36pm, Wednesday, 27'th May 2026
Hims & Hers and Tempus AI are taking different paths in AI-driven healthcare, but which stock offers stronger upside now? Let's dive in.
Hims & Hers Shares Rally On Million-Dollar Insider Purchase
10:54am, Wednesday, 27'th May 2026
Shares of Hims & Hers Health Inc (NYSE:HIMS) are trading higher Wednesday morning, fueled by a wave of investor confidence following an insider stock purchase by a key member of the company's leadersh
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
02:55pm, Tuesday, 26'th May 2026
Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America sa
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
10:54am, Tuesday, 26'th May 2026
Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral...
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
10:01am, Tuesday, 26'th May 2026
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Deepens Personalized Care Through Platform Expansion
11:31am, Friday, 22'nd May 2026
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
09:03am, Thursday, 21'st May 2026
Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster drug Ozempic, through
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
09:00am, Thursday, 21'st May 2026
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible cus
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
09:00am, Thursday, 21'st May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada.
Hims & Hers: Wegovy Deal Fuels Growth
10:08am, Wednesday, 20'th May 2026
Hims & Hers, Inc. (HIMS) stock has risen 41% since my last update, driven by product and international expansion. Q1 revenue reached $608 million, up 4% YoY, with U.S. operations declining but interna
Hims & Hers Massive Stock Drop Explained
02:06pm, Tuesday, 19'th May 2026
Raising debt increases the risk in Hims and Hers' stock.
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering
12:33pm, Tuesday, 19'th May 2026
Hims and Hers Health (HIMS) has priced a larger $350 million private offering of 0.00% convertible senior notes due 2032, up from the previously announced $300 mi
Hims & Hers Stock Stabilizes After Upsized $350 Million Convertible Note Offering
09:16am, Tuesday, 19'th May 2026
Hims & Hers Health Inc (NYSE:HIMS) shares are trading flat during Tuesday's pre-market session as traders continue to digest the company's convertible notes offering.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of
